Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Corticosteroids, anti-CD20 antibody
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Durham, North Carolina + 1 more
Conditions
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Interventions
Autoantibody Reductive Therapy, Treatment as Usual (TAU)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Philadelphia, Pennsylvania + 3 more
Conditions
Cytokine Release Syndrome, COVID19
Interventions
Therapeutic Plasma Exchange, Ruxolitinib
Procedure · Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
12 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Greenville, South Carolina
Conditions
Age-Related Frailty
Interventions
Therapeutic Plasma Exchange (TPE)
Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
50 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Completed Phase 4 Interventional Results available

Octaplas Pediatric Plasma Exchange Trial

NCT01938378
Conditions
Adverse Effects in the Therapeutic Use of Plasma Substitutes
Interventions
Octaplas™
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 20 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • New Orleans, Louisiana + 5 more
Conditions
Therapeutic Plasma Exchange, Anticoagulant Therapy
Interventions
Active Comparator: centrifuge TPE with citrate, Active Comparator: Filter TPE with heparin, Active comparator: Filter TPE with citrate
Device · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
0 Years to 24 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Aging
Interventions
Sham, Therapeutic Plasma Exchange, IVIG
Device · Drug
Lead sponsor
Dobri Kiprov
Industry
Eligibility
50 Years to 95 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Mill Valley, California
Conditions
Immune-related Adverse Event
Interventions
Spectra Optia Apheresis System
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Terminated No phase listed Observational

Octaplas Adult TTP Trial

NCT01938404
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Octaplas, Standard Plasma
Biological · Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Manhasset, New York • Rochester, New York
Conditions
Autoimmune Diseases, Renal Disorders, Hematologic Disorders, Oncologic Disorders
Interventions
Therapeutic plasma exchange
Device
Lead sponsor
Fenwal, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • Rochester, Minnesota • Charlottesville, Virginia + 1 more
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
COVID-19
Interventions
Therapeutic plasma exchange
Device
Lead sponsor
Larkin Community Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
South Miami, Florida
Conditions
COVID-19
Interventions
Therapeutic plasma exchange (TPE), Standard of care
Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia